H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on CRMD stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Cormedix’s promising outlook. The company has shown strong financial performance, with impressive net revenue and earnings figures driven by the increased utilization of DefenCath, particularly among outpatient dialysis customers. This robust financial health is further supported by the recent acquisition of Melinta, which diversifies Cormedix’s business and is expected to bring significant synergies.
Additionally, Cormedix’s pipeline presents multiple catalysts for growth. The anticipated data from the Rezzayo study and the TPN Phase 3 data for DefenCath in early 2026, along with the potential of Niyad in the hospital anticoagulant market, offer substantial opportunities. Despite the potential challenges posed by TDAPA pricing, these developments provide a favorable risk-reward scenario for investors, justifying the Buy rating.
According to TipRanks, Folkes is an analyst with an average return of -1.2% and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Achieve Life Sciences, and Eupraxia Pharmaceuticals.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $16.00 price target.